Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers

Toxins

Volumn 7, Issue 4, 2015, Pages 1116-1125

  Black, Jonathan D ^a   Lopez, Salvatore ^b   Cocco, Emiliano ^a   Schwab, Carlton L ^a   English, Diana P ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Claudin; Clostridium perfringens enterotoxin; Diagnostics; Gynecologic cancer; Therapeutics

Indexed keywords

BETA TUBULIN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 6; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; DOXORUBICIN; ENTEROTOXIN; PACLITAXEL; PLATINUM; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENTEROTOXIN, CLOSTRIDIUM;

APOPTOSIS; BRAIN METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOTHERAPY; CLOSTRIDIUM PERFRINGENS; CYTOLYSIS; CYTOTOXICITY; ENDOMETRIUM CARCINOMA; FEMALE GENITAL TRACT CANCER; HUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; TUMOR GROWTH; TUMOR RECURRENCE; ANIMAL; BINDING SITE; FEMALE; GENITAL NEOPLASMS, FEMALE; METABOLISM; PROTEIN TERTIARY STRUCTURE;

CLOSTRIDIUM PERFRINGENS;

ANIMALS; BINDING SITES; CLAUDIN-3; CLAUDIN-4; ENTEROTOXINS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PROTEIN STRUCTURE, TERTIARY;

EID: 84928956897     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins7041116     Document Type: Review

References (56)

1. McClane, B.A. An overview of Clostridium perfringens enterotoxin. Toxicon 1996, 34, 1335–1343.
2. Kokai-Kun, J.F.; McClane, B.A. Evidence that a region(s) of the Clostridium perfringens enterotoxin molecule remains exposed on the external surface of the mammalian plasma membrane when the toxin is sequestered in small or large complexes. Infect. Immun. 1996, 64, 1020–1025.
3. Kokai-Kun, J.F.; McClane, B.A. Determination of functional regions of Clostridium perfringens enterotoxin through deletion analysis. Clin. Infect. Dis. 1997, 25, S165–S167.
4. Kokai-Kun, J.F.; McClane, B.A. Deletion analysis of the Clostridium perfringens enterotoxin. Infect. Immun. 1997, 65, 1014–1022.
5. Miyamoto, K.; Fisher, D.J.; Li, J.; Sayeed, S.; Akimoto, S.; McClane, B.A. Complete sequencing and diversity analysis of the enterotoxin-encoding plasmids in Clostridium perfringens type A non-food-borne human gastrointestinal disease isolates. J. Bacteriol. 2006, 188, 1585–1598.
6. McClane, B.A.; Chakrabarti, G. New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin. Anaerobe 2004, 10, 107–114.
7. Hanna, P.C.; Mietzner, T.A.; Schoolnik, G.K.; McClane, B.A. Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region. J. Biol. Chem. 1991, 266, 11037–11043.
8. English, D.P.; Santin, A.D. Claudins overexpression in ovarian cancer: Potential targets for Clostridium perfringens enterotoxin (CPE) based diagnosis and therapy. Int. J. Mol. Sci. 2013, 14, 10412–10437.
9. Long, H.; Crean, C.D.; Lee, W.H.; Cummings, O.W.; Gabig, T.G. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001, 61, 7878–7881.
10. Lal-Nag, M.; Battis, M.; Santin, A.D.; Morin, P.J. Claudin-6: A novel receptor for CPE-mediated cytotoxicity in ovarian cancer. Oncogenesis 2012, 1, e33.
11. Shrestha, A.; McClane, B.A. Human claudin-8 and -14 are receptors capable of conveying the cytotoxic effects of Clostridium perfringens enterotoxin. MBio 2013, doi:10.1128/mBio.00594-12/
12. Katahira, J.; Sugiyama, H.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J. Biol. Chem. 1997, 272, 26652–26658.
13. Katahira, J.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell. Biol. 1997, 136, 1239–1247.
14. Du Bois, A.; Lück, H.J.; Meier, W.; Adams, H.P.; Möbus, V.; Costa, S.; Bauknecht, T.; Richter, B.; Warm, M.; Schröder, W.; et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003, 95, 1320–1329.
15. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002, 360, 505–515.
16. Moxley, K.M.; McMeekin, D.S. Endometrial carcinoma: A review of chemotherapy, drug resistance, and the search for new agents. Oncologist 2010, 15, 1026–1033.
17. Shen, D.W.; Pouliot, L.M.; Hall, M.D.; Gottesman, M.M. Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2012, 64, 706–721.
18. Markman, M.; Bookman, M.A. Second-line treatment of ovarian cancer. Oncologist 2000, 5, 26–35.
19. Naumann, R.W.; Coleman, R.L. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011, 71, 1397–1412.
20. Lortholary, A.; Largillier, R.; Weber, B.; Gladieff, L.; Alexandre, J.; Durando, X.; Slama, B.; Dauba, J.; Paraiso, D.; Pujade-Lauraine, E. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann. Oncol. 2012, 23, 346–352.
21. Casagrande, F.; Cocco, E.; Bellone, S.; Richter, C.E.; Bellone, M.; Todeschini, P.; Siegel, E.; Varughese, J.; Arin-Silasi, D.; Azodi, M.; et al. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 2011, 117, 5519–5528.
22. Stewart, J.J.; White, J.T.; Yan, X.; Collins, S.; Drescher, C.W.; Urban, N.D.; Hood, L.; Lin, B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 2006, 5, 433–443.
23. Santin, A.D.; Cané, S.; Bellone, S.; Palmieri, M.; Siegel, E.R.; Thomas, M.; Roman, J.J.; Burnett, A.; Cannon, M.J.; Pecorelli, S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005, 65, 4334–4342.
24. Coleman, R.E.; Harper, P.G.; Gallagher, C.; Osborne, R.; Rankin, E.M.; Silverstone, A.C.; Slevin, M.L.; Souhami, R.L.; Tobias, J.S.; Trask, C.W. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother. Pharmacol. 1986, 18, 280–283.
25. Sutton, G.P.; Blessing, J.A.; McGuire, W.P.; Patton, T.; Look, K.Y. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A Gynecologic Oncology Group study. Am. J. Obstet. Gynecol. 1993, 168, 805–807.
26. Monk, B.J.; Sill, M.W.; Burger, R.A.; Gray, H.J.; Buekers, T.E.; Roman, L.D. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J. Clin. Oncol. 2009, 27, 1069–1074.
27. Poolkerd, S.; Leelahakorn, S.; Manusirivithaya, S.; Tangjitgamol, S.; Thavaramara, T.; Sukwattana, P.; Pataradule, K. Survival rate of recurrent cervical cancer patients. J. Med. Assoc. Thail. 2006, 89, 275–282.
28. Furuse, M.; Fujita, K.; Hiiragi, T.; Fujimoto, K.; Tsukita, S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell. Biol. 1998, 141, 1539–1550.
29. Morita, K.; Furuse, M.; Fujimoto, K.; Tsukita, S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA 1999, 96, 511–516.
30. Günzel, D.; Fromm, M. Claudins and other tight junction proteins. Compr. Physiol. 2012, 2, 1819–1852.
31. Hough, C.D.; Sherman-Baust, C.A.; Pizer, E.S.; Montz, F.J.; Im, D.D.; Rosenshein, N.B.; Cho, K.R.; Riggins, G.J.; Morin, P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60, 6281–6287.
32. Santin, A.D.; Zhan, F.; Cane, S.; Bellone, S.; Palmieri, M.; Thomas, M.; Burnett, A.; Roman, J.J.; Cannon, M.J.; Shaughnessy, J., Jr.; et al. Gene expression fingerprint of uterine serous papillary carcinoma: Identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br. J. Cancer 2005, 92, 1561–1573.
33. Soini, Y. Claudins 2, 3, 4, and 5 in Paget’s disease and breast carcinoma. Hum. Pathol. 2004, 35, 1531–1536.
34. Michl, P.; Barth, C.; Buchholz, M.; Lerch, M.M.; Rolke, M.; Holzmann, K.H.; Menke, A.; Fensterer, H.; Giehl, K.; Löhr, M.; et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003, 63, 6265–6271.
35. De Souza, W.F.; Fortunato-Miranda, N.; Robbs, B.K.; de Araujo, W.M.; de-Freitas-Junior, J.C.; Bastos, L.G.; Viola, J.P.B.; Morgado-Díaz, J.A. Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: Roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. PLoS One 2013, 8, e74994.
36. Kolokytha, P.; Yiannou, P.; Keramopoulos, D.; Kolokythas, A.; Nonni, A.; Patsouris, E.; Pavlakis, K. Claudin-3 and claudin-4: Distinct prognostic significance in triple-negative and luminal breast cancer. Appl. Immunohistochem. Mol. Morphol. 2014, 22, 125–131.
37. Santin, A.D.; Bellone, S.; Siegel, E.R.; McKenney, J.K.; Thomas, M.; Roman, J.J.; Burnett, A.; Tognon, G.; Bandiera, E.; Pecorelli, S. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin. Cancer Res. 2007, 13, 3339–3346.
38. Santin, A.D.; Zhan, F.; Bellone, S.; Palmieri, M.; Cane, S.; Bignotti, E.; Anfossi, S.; Gokden, M.; Dunn, D.; Roman, J.J.; et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 2004, 112, 14–25.
39. Fujita, K.; Katahira, J.; Horiguchi, Y.; Sonoda, N.; Furuse, M.; Tsukita, S. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett. 2000, 476, 258–261.
40. Cocco, E.; Casagrande, F.; Bellone, S.; Richter, C.E.; Bellone, M.; Todeschini, P.; Holmberg, J.C.; Fu, H.H.; Montagna, M.K.; Mor, G.; et al. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10, 349.
41. Morin, P.J. Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Res. 2005, 65, 9603–9606.
42. Kominsky, S.L.; Vali, M.; Korz, D.; Gabig, T.G.; Weitzman, S.A.; Argani, P.; Sukumar, S. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol. 2004, 164, 1627–1633.
43. Maeda, T.; Murata, M.; Chiba, H.; Takasawa, A.; Tanaka, S.; Kojima, T.; Masumori, N.; Tsukamoto, T.; Sawada, N. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. Prostate 2012, 72, 351–360.
44. Michl, P.; Buchholz, M.; Rolke, M.; Kunsch, S.; Löhr, M.; McClane, B.; Tsukita, S.; Leder, G.; Adler, G.; Gress, T.M. Claudin-4: A new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001, 121, 678–684.
45. Birks, D.K.; Kleinschmidt-DeMasters, B.K.; Donson, A.M.; Barton, V.N.; McNatt, S.A.; Foreman, N.K.; Handler, M.H. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010, 20, 140–150.
46. Kondoh, M.; Takahashi, A.; Fujii, M.; Yagi, K.; Watanabe, Y. A novel strategy for a drug delivery system using a claudin modulator. Biol. Pharm. Bull. 2006, 29, 1783–1789.
47. Gao, Z.; Xu, X.; McClane, B.; Zeng, Q.; Litkouhi, B.; Welch, W.R.; Berkowitz, R.S.; Mok, S.C.; Garner, E.I.O. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin. Clin. Cancer Res. 2011, 17, 1065–1074.
48. Yuan, X.; Lin, X.; Manorek, G.; Kanatani, I.; Cheung, L.H.; Rosenblum, M.G.; Howell, S.B. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol. Cancer Ther. 2009, 8, 1906–1915.
49. Yoshida, H.; Sumi, T.; Zhi, X.; Yasui, T.; Honda, K.I.; Ishiko, O. Claudin-4: A potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res. 2011, 31, 1271–1277.
50. Litkouhi, B.; Kwong, J.; Lo, C.M.; Smedley, J.G., 3rd.; McClane, B.A.; Aponte, M.; Gao, Z.; Sarno, J.L.; Hinners, J.; et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 2007, 9, 304–314.
51. Kominsky, S.L.; Tyler, B.; Sosnowski, J.; Brady, K.; Doucet, M.; Nell, D.; Smedley, J.G.; McClane, B.; Brem, H.; Sukumar, S. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res. 2007, 67, doi:10.1158/0008-5472.can-07-1314.
52. Walther, W.; Petkov, S.; Kuvardina, O.N.; Aumann, J.; Kobelt, D.; Fichtner, I.; Lemm, M.; Piontek, J.; Blasig, I.E.; Stein, U. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther. 2012, 19, 494–503.
53. Van Dam, G.M.; Themelis, G.; Crane, L.M.A.; Harlaar, N.J.; Pleijhuis, R.G.; Kelder, W.; Sarantopoulos, A.; de Jong, J.S.; Arts, H.J.G.; van der Zee, A.G.J.; et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat. Med. 2011, 17, 1315–1319.
54. Boente, M.P.; Godwin, A.K.; Hogan, W.M. Screening, imaging, and early diagnosis of ovarian cancer. Clin. Obstet. Gynecol. 1994, 37, 377–391.
55. Schwartz, P.E. The management of serous papillary uterine cancer. Curr. Opin. Oncol. 2006, 18, 494–499.
56. Facchetti, F.; Lonardi, S.; Gentili, F.; Bercich, L.; Falchetti, M.; Tardanico, R.; Baronchelli, C.; Lucini, L.; Santin, A.; Murer, B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows. Arch. 2007, 451, 669–680.